Evaluating genetically-predicted causal effects of lipoprotein(a) in human diseases: a phenome-wide Mendelian randomization study

Jingchunzi Shi,Suyash S. Shringarpure,David Hinds,23andMe Research Team,Adam Auton,Michael V. Holmes

DOI: https://doi.org/10.1101/2024.07.24.24310950

2024-07-25

Abstract:Background: Lipoprotein(a) (Lp[a]) is a circulating plasma lipoprotein that is emerging as an important independent risk factor for vascular disease. Lp(a) levels are 75-90% heritable, predominantly determined by copy number variation and single nucleotide polymorphisms (SNPs) at the LPA gene. Methods: Using ~370K individuals with serum measurements of Lp(a) in the UK Biobank European cohort, we constructed a genetic risk score (GRS) consisting of 29 SNPs in the vicinity of LPA which explained 68.18% of variation in Lp(a). Using the LPA GRS to instrument Lp(a), we conducted phenome-wide Mendelian randomization analysis (MR-PheWAS) across a spectrum of 489 medically-relevant phenotypes in ~7.3M individuals from the 23andMe, Inc. database, and compared effects to those derived from a GRS for low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB). Through multivariable MR, we sought to assess the direct causal effect of Lp(a) on cardiovascular disease risks while keeping LDL-C or apoB constant. Results: MR-PheWAS confirmed previously reported Lp(a) causal effects on coronary artery disease (CAD: OR = 1.199, 95% CI = [1.193, 1.205], p-value < 2.23e-308, for every 59.632 nmol/L higher Lp(a) instrumented by the LPA GRS), and revealed additional genetically-predicted effects largely confined to cardiovascular endpoints, including a novel effect for restrictive cardiomyopathy (OR = 1.101, 95% CI = [1.068, 1.134], p-value = 3e-10). We scaled the LPA, LDL-C and apoB GRS such that they each had the same OR for MACE (major adverse cardiovascular events). Using the scaling rubric, similar magnitudes of effect were seen for the three lipid traits for most vascular diseases, with the exception of peripheral artery disease, aortic stenosis and dilated cardiomyopathy, where Lp(a) had larger genetically-predicted effect sizes compared to LDL-C and apoB. Multivariable MR identified Lp(a) to retain a causal effect on MACE while accounting for LDL-C or apoB. To achieve the 25% relative risk reduction in major vascular events, as seen with a 1 mmol/L reduction in LDL-C from statin trials, we anticipate that Lp(a) ought to be reduced by ~ 90 mg/dL (200 nmol/L), highlighting the importance of not only using therapies that have a profound impact on Lp(a) lowering, but also selecting individuals that have high Lp(a) concentrations at baseline. Conclusion: Lp(a) has genetically-predicted causal effects on a broad range of cardiovascular diseases beyond CAD, with minimal effects seen for non-vascular disease.

Cardiovascular Medicine

What problem does this paper attempt to address?

The main problem this paper attempts to address is the evaluation of the causal effects of lipoprotein(a) (Lp(a)) in human diseases, particularly its impact on cardiovascular diseases. Specifically, the researchers quantified Lp(a) levels by constructing a genetic risk score (GRS) and systematically assessed the impact of Lp(a) on 489 medically relevant phenotypes in a large population using Mendelian randomization phenome-wide association study (MR-PheWAS) methods. Additionally, the study aimed to compare the relative impact of Lp(a) with low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) on different disease endpoints and to distinguish the direct causal effect of Lp(a) on major adverse cardiovascular events (MACE) through multivariable Mendelian randomization analysis, while considering the influence of LDL-C or apoB.

The core objectives of the paper include:
1. **Systematically exploring the causal role of Lp(a)**: Revealing the broad spectrum of potential beneficial and adverse health outcomes of Lp(a) through Mendelian randomization analysis across the entire phenome.
2. **Comparing the disease association levels of Lp(a) with LDL-C and apoB**: Calibrating the effects of these three lipid markers on composite cardiovascular outcomes to the same effect size for clinically meaningful comparisons.
3. **Evaluating the independent effect of Lp(a) on cardiovascular diseases**: Assessing the direct causal effect of Lp(a) on cardiovascular disease risk through multivariable Mendelian randomization analysis, considering genetically predicted changes in LDL-C or apoB.

Achieving these objectives will help deepen the understanding of the role of Lp(a) in the pathogenesis of cardiovascular diseases and provide scientific evidence for potential future Lp(a)-lowering therapies.